Seattle Times -- Dendreon will have three plants to make its Provenge prostate-cancer drug by mid-2011, said Chief Executive Officer Mitchell Gold. The Seattle-based company will also have a sales force of 125 people to market the drug, he said at a Biotechnology Industry Organization conference in New York.
